Unlike large pharma where novel projects compete with established, safer alternatives, biotech startups derive immense power from their singular focus. The "live or die" mentality on a single hard problem forces teams to innovate and persevere through setbacks, which is essential for pushing true scientific boundaries.

The CEO believes the most profound lessons in biotech come from speaking with founders of companies that did not succeed. In an industry defined by high clinical trial risk, understanding the missteps and navigating the challenges of unsuccessful ventures provides more practical wisdom than studying success stories alone.

Contrary to startup culture, the best training for biotech leadership is gaining broad, cross-functional experience in a large, structured pharmaceutical company. This foundation provides the necessary depth and breadth to navigate the complexities of leading a smaller, resource-constrained biotech later on.

The transition from a leadership role at a large pharma company like Gilead to a biotech CEO involves a massive shift in scope. Instead of managing one large function with a large team, a biotech CEO is hands-on with every aspect of the company, from science to finance.

Alan Bash's biggest learning after moving from Bristol-Myers Squibb to smaller biotechs was the constant pressure of cash runway. Unlike in large pharma where budgets are a concern, in biotech, cash availability dictates all strategic choices, including partnerships and M&A.

Derek Adams began in late-stage vaccine manufacturing at Merck before moving to earlier-stage companies. This "reverse" path provides a deep understanding of commercial realities, operational execution, and scale-up challenges that is invaluable for building a capital-efficient startup from the ground up.

Ron Cooper credits his success not to being a "scaling guy" at Bristol-Myers Squibb, but the "fix-it guy." Being deployed to turn around struggling business units across different geographies and therapeutic areas provided the multicultural, problem-solving toolkit essential for navigating the constant challenges of leading a biotech startup.

The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.

Unlike software startups that can "fail fast" and pivot cheaply, a single biotech clinical program costs tens of millions. This high cost of failure means the industry values experienced founders who have learned from past mistakes, a direct contrast to Silicon Valley's youth-centric culture.